Alemtuzumab for the treatment of multiple sclerosis
Mark D Willis, Neil P Robertson Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, UK Abstract: Alemtuzumab is an anti-CD52 monoclonal antibody, recently approved for the treatment of active, relapsing multiple sclero...
Saved in:
Main Authors: | Willis MD (Author), Robertson NP (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2015-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Alemtuzumab in the treatment of multiple sclerosis
by: Fernandez Ó
Published: (2014) -
Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis
by: Tereza Gabelić, et al.
Published: (2021) -
Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations
by: Dörr J, et al.
Published: (2016) -
Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
by: Guarnera C, et al.
Published: (2017) -
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
by: Havrdova E, et al.
Published: (2017)